- Home
- IMCR vs AKRO Comparison
IMCR vs AKRO Comparison
Compare IMCR & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- AKRO
- Stock Information
- Founded
- IMCR 2008
- AKRO 2017
- Country
- IMCR United Kingdom
- AKRO United States
- Employees
- IMCR N/A
- AKRO N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- IMCR Health Care
- AKRO Health Care
- Exchange
- IMCR Nasdaq
- AKRO Nasdaq
- Market Cap
- IMCR 1.7B
- AKRO 2.1B
- IPO Year
- IMCR 2021
- AKRO 2019
- Fundamental
- Price
- IMCR $32.93
- AKRO $31.59
- Analyst Decision
- IMCR Buy
- AKRO Strong Buy
- Analyst Count
- IMCR 14
- AKRO 7
- Target Price
- IMCR $74.75
- AKRO $43.20
- AVG Volume (30 Days)
- IMCR 267.8K
- AKRO 441.5K
- Earning Date
- IMCR 11-05-2024
- AKRO 11-11-2024
- Dividend Yield
- IMCR N/A
- AKRO N/A
- EPS Growth
- IMCR N/A
- AKRO N/A
- EPS
- IMCR N/A
- AKRO N/A
- Revenue
- IMCR $280,914,000.00
- AKRO N/A
- Revenue This Year
- IMCR $25.60
- AKRO N/A
- Revenue Next Year
- IMCR $10.63
- AKRO N/A
- P/E Ratio
- IMCR N/A
- AKRO N/A
- Revenue Growth
- IMCR 27.95
- AKRO N/A
- 52 Week Low
- IMCR $29.72
- AKRO $11.36
- 52 Week High
- IMCR $76.98
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- IMCR 52.76
- AKRO 66.34
- Support Level
- IMCR $31.10
- AKRO $29.34
- Resistance Level
- IMCR $35.47
- AKRO $32.15
- Average True Range (ATR)
- IMCR 1.49
- AKRO 1.26
- MACD
- IMCR 0.17
- AKRO 0.10
- Stochastic Oscillator
- IMCR 51.98
- AKRO 99.74
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.